Share on StockTwits

Shares of Versartis (NASDAQ:VSAR) were the recipient of a significant growth in short interest in the month of April. As of April 30th, there was short interest totalling 950,825 shares, a growth of 42.3% from the April 15th total of 668,324 shares, AnalystRatings.NET reports. Based on an average trading volume of 165,501 shares, the days-to-cover ratio is presently 5.7 days. Approximately 13.5% of the shares of the company are short sold.

A number of analysts have recently weighed in on VSAR shares. Analysts at Zacks initiated coverage on shares of Versartis in a research note on Wednesday, April 23rd. They set a “hold” rating on the stock. Separately, analysts at Cowen and Company initiated coverage on shares of Versartis in a research note on Tuesday, April 15th. They set an “outperform” rating and a $45.00 price target on the stock. Finally, analysts at Canaccord Genuity initiated coverage on shares of Versartis in a research note on Tuesday, April 15th. They set a “buy” rating and a $36.00 price target on the stock. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $55.00.

Shares of Versartis (NASDAQ:VSAR) opened at 27.53 on Monday. Versartis has a 1-year low of $23.51 and a 1-year high of $36.30. The stock has a 50-day moving average of $28.30 and a 200-day moving average of $28.59. The company’s market cap is $640.3 million.

Versartis (NASDAQ:VSAR) last issued its quarterly earnings data on Monday, May 5th. The company reported ($2.57) earnings per share (EPS) for the quarter, beating the consensus estimate of ($6.37) by $3.80. On average, analysts predict that Versartis will post $-10.58 earnings per share for the current fiscal year.

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is initially developing its long-acting recombinant human growth hormone, VRS-317, for growth hormone deficiency (NASDAQ:VSAR), an orphan disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.